Folprecht G, Reinacher-Schick A, Weitz J, et al. - The CIRCULATE trial may establish circulating tumor (ct)DNA for adjuvant treatment decision in stage II colon cancer – and with the secondary aims – promote a ctDNA guided follow up in colon cancer stage II and beyond.

• In individuals with early stage and resected colorectal cancer, ctDNA is a prognostic biomarker of recurrence.

• The CIRCULATE trial looks at the prognostic value of ctDNA for adjuvant treatment in stage II colon cancer.

• A total of 231 patients with detectable ctDNA (ctDNApos) after resection are randomized 2:1 to chemotherapy or to control (follow-up).

• Patients with no detectable ctDNA (about 2,079 patients) are randomly assigned 1:4 to the control or off-study groups.

• Disease-free survival is the primary endpoint.